Resources for healthcare professionals

Expert lead video content, congress highlights and downloadable resources for healthcare professionals about ovarian cancer.

Congress & GSK webinar videos

Evaluating the new first-line maintenance treatment options in AOC – who should get what? (presented at BGCS virtual meeting 2021) (5 mins)

Dr Susana Banerjee

Expert perspectives

The role of HRD testing and the challenges of COVID-19 in advanced ovarian cancer treatment (11 mins)

Professor Jonathan Ledermann, Professor Marcia Hall

 Understanding HRD testing and its importance – Part 1 of 3

Understanding the challenges associated with HRD testing in the clinical setting – Part 2 of 3

Considerations when prescribing Niraparib for the treatment of adult patients with ovarian cancer – A patient case study – Part 3 of 3

Link to prescribing information can be found at the top of this page.

Downloadable resources

ZEJULA key information PDF

ZEJULA in PRIMA and PRIME

ZEJULA SMC reimbursement

ZEJULA reimbursement in Scotland

Image of a fictitious healthcare professional speaking to a fictitious patient
How can ZEJULA help your next patient?

ZEJULA is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinumsensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Footnotes

AOC, advanced ovarian cancer; BGCS, British Gynaecological Cancer Society; BOPA, British Oncology Pharmacy Association; HCP, healthcare professional; HRD, homologous recombination deficiency; MoA, mechanism of action; PARPi, poly (ADP-ribose) polymerase inhibitors; QoL, quality of life; SMC, Scottish Medicines Consortium

References

  1. ZEJULA Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 4411 or UKSafety@gsk.com

© 2022 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

July 2022 | PM-GB-NRP-WCNT-210023 (V1.0)